115 related articles for article (PubMed ID: 23247067)
1. Hepatitis C infection and presence of advanced fibrosis: wait or treat? Why wait? There is no time to lose, is there?
Tillmann HL
J Hepatol; 2013 Mar; 58(3):412-4. PubMed ID: 23247067
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
[TBL] [Abstract][Full Text] [Related]
3. Boceprevir for HCV in patients with HIV: where next?
Osinusi A; Naggie S
Lancet Infect Dis; 2013 Jul; 13(7):563-4. PubMed ID: 23768748
[No Abstract] [Full Text] [Related]
4. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection: resolved and unresolved issues.
Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):26-30. PubMed ID: 24199625
[TBL] [Abstract][Full Text] [Related]
5. A modified ribavirin-free interferon therapy with boceprevir in post-liver transplant recurrent hepatitis C.
Maticic M; Luznik Z; Stepec S; Popovic P; Snedec N; Poljak M; Stanisavljevic D
J Clin Gastroenterol; 2014; 48(5):464-5. PubMed ID: 24275712
[No Abstract] [Full Text] [Related]
6. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
7. A crossing in therapy for hepatitis C virus genotype 2 or 3: increasing ribavirin dose with shortened duration or reducing ribavirin dose with standard duration.
Huang CF; Dai CY; Huang JF; Chuang WL; Yu ML
Hepatology; 2009 Apr; 49(4):1395-6; author reply 1396. PubMed ID: 19330867
[No Abstract] [Full Text] [Related]
8. Shortened therapy for hepatitis C virus genotype 2 or 3--is less more?
Liang TJ
N Engl J Med; 2007 Jul; 357(2):176-8. PubMed ID: 17625131
[No Abstract] [Full Text] [Related]
9. One step forward in understanding the differences in antiviral response to interferon a2a and a2b in chronic hepatitis C patients with advanced fibrosis.
Shouval D
J Hepatol; 2012 Feb; 56(2):303-4. PubMed ID: 22015961
[No Abstract] [Full Text] [Related]
10. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.
Med Lett Drugs Ther; 2011 Jul; 53(1369):57-9. PubMed ID: 21778964
[No Abstract] [Full Text] [Related]
11. [High dosage induction brings new hope].
MMW Fortschr Med; 2005 Dec; 147(51-52):68. PubMed ID: 16404784
[No Abstract] [Full Text] [Related]
12. Adding telaprevir improves cure rate in patient with HCV infection.
AIDS Patient Care STDS; 2010 Dec; 24(12):807. PubMed ID: 21188771
[No Abstract] [Full Text] [Related]
13. Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
Kawaoka T; Hiraga N; Takahashi S; Takaki S; Tsuge M; Nagaoki Y; Hashimoto Y; Katamura Y; Miki D; Hiramatsu A; Waki K; Imamura M; Kawakami Y; Aikata H; Ochi H; Tashiro H; Ohdan H; Chayama K
Intervirology; 2012; 55(4):306-10. PubMed ID: 21865660
[TBL] [Abstract][Full Text] [Related]
14. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
[TBL] [Abstract][Full Text] [Related]
15. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
Bruno S; Shiffman ML; Roberts SK; Gane EJ; Messinger D; Hadziyannis SJ; Marcellin P
Hepatology; 2010 Feb; 51(2):388-97. PubMed ID: 19918980
[TBL] [Abstract][Full Text] [Related]
17. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
18. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
[TBL] [Abstract][Full Text] [Related]
19. Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S; Lyden E
Hepatogastroenterology; 2006; 53(70):561-5. PubMed ID: 16995462
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
